Both the DCLD and CLD patients experienced statistically significant decreases in SGOT, SGPT, serum alkaline phosphatase, and INR levels, along with increased serum albumin at 12 weeks, 24 weeks, and 6 months post-therapy follow-up, indicating improvement in liver function tests. The gene discussed is ALB; the disease is congenital secretory chloride diarrhea 1.